MetaCap

Curis (CRIS) vs Scilex (SCLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Curis is the larger company by market cap ($4.1 million vs $4.0 million), about 1.0 times the size. Curis converts more of its revenue into profit, with a net margin of -80.3% versus -1236.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRIS-42.03%SCLX-83.79%
+57%-17%-91%
Oct 7, 20261 yearNov 20, 2026
CRIS-36.38%SCLX-80.62%
+41%-23%-86%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRIS versus SCLX key metrics
MetricCRISSCLX
Share price$0.427$0.5658
Market cap$4.06M$3.98M
1-day change-9.03%-12.95%
YTD return—-92.55%
1-year return—-95.96%
5-year return—-99.74%
P/E ratio (TTM)0.03—
Forward P/E—0.78
EPS (TTM)$15.43$-49.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$9.44M$30.25M
Revenue growth (YoY)-13.43%-46.54%
Net income (latest FY)$-7.58M$-374.05M
Gross margin—415.83%
Operating margin-60.50%-1143.71%
Net margin-80.29%-1236.42%
52-week high$28.40$14.34
52-week low$0.33$0.50
Distance from 52-week high-98.50%-96.05%
Analyst consensusnone—
Avg. price target upside+9892.97%—
Average volume4.33M56.11K
Shares outstanding9.51M7.03M
Employees2034
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Curis is more profitable, keeping -80.3 cents of every revenue dollar as net income versus -1236.4 cents for Scilex.
  • Curis grew revenue faster in its latest fiscal year (-13.43% vs -46.54%).

About Curis

CRIS stock →

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

CRIS vs SCLX FAQ

Which is bigger, Curis or Scilex?

Curis (CRIS) is larger, with a market capitalization of $4.06M compared with $3.98M for Scilex (SCLX).

Are Curis and Scilex in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons